Liposomal Doxorubicin Market Analysis By Product (J&J [Doxil/Caelyx], Sun Pharma [Lipodox], Teva [Myocet], Others), By Application (Multiple Myeloma, Kaposi Sarcoma, Ovarian, Breast, Kidney Cancer), And Segment Forecasts, 2018 - 2024

Table of Content

Chapter 1 Research Methodology
                   1.1 Information Procurement
                      1.1.1 Purchased database:
                      1.1.2 GVR’s Internal Database
                   1.2 Primary Research:
                      1.2.1 List of primary sources include:
Chapter 2 Executive Summary
                   2.1 Market Snapshot
Chapter 3 Liposomal Doxorubicin Market Variables, Trends & Scope
                   3.1 Market Segmentation
                   3.2 Market Driver Analysis
                      3.2.1 Increasing number of market players
                      3.2.2 Increasing application of doxorubicin
                      3.2.3 Growing number of cancer cases
                   3.3 Market Restraint Analysis
                      3.3.1 Supply Demand Gap
                   3.4 Key Opportunities Prioritized
                   3.5 Liposomal Doxorubicin Market- PESTEL Analysis
                   3.6 Industry Analysis - Porter’s
                   3.7 Product Pipeline Analysis, 2015
                   3.8 Heat Map Analysis: Doxorubicin market, 2014
Chapter 4 Market Categorization 1: Product Estimates & Trend Analysis
                   4.1 Liposomal Doxorubicin Market: Product Movement Analysis
                   4.2 J&J (Doxil/Caelyx)
                      4.2.1 J&J (Doxil/ Caelyx) market estimates and forecasts, 2013 - 2024 (USD Million)
                   4.3 Sun Pharmaceuticals Industries Ltd (Lipodox)
                      4.3.1 Sun Pharma (Lipodox) market estimates and forecasts, 2013 - 2024 (USD Million)
                   4.4 Teva (Myocet)
                      4.4.1 Teva (Myocet) market estimates and forecasts, 2013 - 2024 (USD Million)
                   4.5 Others
                      4.5.1 Others market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 5 Market Categorization 2: Application Estimates & Trend Analysis
                   5.1 Liposomal Doxorubicin Market: Application Movement Analysis
                   5.2 Leukemia
                      5.2.1 Leukemia market estimates and forecasts, 2013 - 2024 (USD Million)
                   5.3 Bone Sarcoma
                      5.3.1 Bone Sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
                   5.4 Breast Cancer
                      5.4.1 Breast cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                   5.5 Endometrial Cancer
                      5.5.1 Endometrial cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                   5.6 Gastric Cancer
                      5.6.1 Gastric cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                   5.7 Liver cancer
                      5.7.1 Liver cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                   5.8 Kidney Cancer
                      5.8.1 Kidney cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                   5.9 Multiple Myeloma
                      5.9.1 Multiple myeloma market estimates and forecasts, 2013 - 2024 (USD Million)
                   5.10 Ovarian Cancer
                      5.10.1 Ovarian cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                   5.11 Kaposi Sarcoma
                      5.11.1 Kaposi sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
                   5.12 Other Cancer
                      5.12.1 Other cancer applications market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 6 Market Categorization 3: Regional Estimates & Trend Analysis, by Product and Application
                   6.1 Liposomal Doxorubicin Market Share, by Region, 2015 & 2024
                   6.2 North America
                      6.2.1 North America liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                      6.2.2 The U.S.
                      6.2.3 U.S. liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                      6.2.4 Canada
                      6.2.5 Canada liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                   6.3 Europe
                      6.3.1 Europe liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                      6.3.2 Germany
                      6.3.3 Germany liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                      6.3.4 UK
                      6.3.5 UK liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                   6.4 Asia Pacific
                      6.4.1 Asia Pacific liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                      6.4.2 Japan
                      6.4.3 Japan liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                      6.4.4 China
                      6.4.5 China liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                   6.5 Latin America
                      6.5.1 Latin America liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                      6.5.2 Brazil
                      6.5.3 Brazil liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                      6.5.4 Mexico
                      6.5.5 Mexico liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                   6.6 MEA
                      6.6.1 MEA liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
                      6.6.2 South Africa
                      6.6.3 South Africa liposomal doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 7 Competitive Landscape
                   7.1 Pfizer, Inc.
                      7.1.1 Company overview
                      7.1.2 Financial performance
                      7.1.3 Product benchmarking
                   7.2 Sun Pharmaceutical Industries Ltd.
                      7.2.1 Company overview
                      7.2.2 Financial performance
                      7.2.3 Product benchmarking
                      7.2.4 Strategic initiatives
                   7.3 Cipla, Inc.
                      7.3.1 Company overview
                      7.3.2 Financial performance
                      7.3.3 Product benchmarking
                      7.3.4 Strategic initiatives
                   7.4 Cadila Pharmaceuticals
                      7.4.1 Company overview
                      7.4.2 Financial performance
                      7.4.3 Product benchmarking
                   7.5 Teva Pharmaceuticals Industries Ltd.
                      7.5.1 Company overview
                      7.5.2 Financial performance
                      7.5.3 Product benchmarking
                      7.5.4 Strategic initiatives
                   7.6 Janssen Products, LP
                      7.6.1 Company overview
                      7.6.2 Financial performance
                      7.6.3 Product benchmarking
                      7.6.4 Strategic initiatives

List of Tables

TABLE 1 Approved doxorubicin products, by approval date and company name
TABLE 2 Estimated number of cancer cases and deaths, by type in 2016
TABLE 3 Cancer Prevalence, by type and region in 2012
TABLE 4 Product launches build in the pipeline
TABLE 5 Commercially available products, by brand name and countries
TABLE 6 Commercially available products, by brand name and countries
TABLE 7 Commercially available products, by brand name and countries
TABLE 8 North America liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 9 North America liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 10 Estimated new cases of cancer, by type and age, 2015
TABLE 11 U.S. liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 12 U.S. liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 13 Canada liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 14 Canada liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 15 Europe liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 16 Europe liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 17 Germany liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 18 Germany liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 19 UK liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 20 UK liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 21 Asia Pacific liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 22 Asia Pacific liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 23 Number of cancer cases by site in 2015
TABLE 24 Japan liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 25 Japan liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 26 China liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 27 China liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 28 Latin America liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 29 Latin America liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 30 Brazil liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 31 Brazil liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 32 Mexico liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 33 Mexico liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 34 MEA liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 35 MEA liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)
TABLE 36 South Africa liposomal doxorubicin market, by product, 2013 - 2024 (USD Million)
TABLE 37 South Africa liposomal doxorubicin market, by application, 2013 - 2024 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market summary
FIG. 5 Market trends & outlook
FIG. 6 Market segmentation & scope
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 U.S. Estimated number of cancer cases and death, by type in 2016
FIG. 9 Market restraint relevance analysis (Current & future impact)
FIG. 10 Key Opportunities Prioritized
FIG. 11 Liposomal doxorubicin PESTEL analysis
FIG. 12 Porter’s Five Forces Analysis
FIG. 13 Heat map analysis
FIG. 14 Liposomal doxorubicin market: Product outlook key takeaways
FIG. 15 Liposomal doxorubicin market: Product movement analysis
FIG. 16 Global J&J (Doxil/ Caelyx) market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 17 Global Sun Pharma (Lipodox) market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 18 Global Teva (Myocet) market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 19 Global other products market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 20 Liposomal doxorubicin market application outlook: Key takeaways
FIG. 21 Liposomal doxorubicin market: Application movement analysis
FIG. 22 Leukemia market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 23 Bone sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 24 Breast cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 25 Endometrial cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 26 Gastric cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 27 Liver cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 28 Kidney cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 29 Multiple myeloma market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 30 Ovarian market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 31 Kaposi sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 32 Other cancer application market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 33 Regional market place: Key takeaways
FIG. 34 Regional outlook, 2015 & 2024
FIG. 35 North America doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 36 U.S. doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 37 Canada doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 38 Europe doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 39 Germany doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 40 UK Doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 41 Asia Pacific doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 42 Japan doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 43 China doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 44 Latin America number of new cancer cases, by application, 2012
FIG. 45 Latin America doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 46 Brazil doxorubicin market estimates, and forecasts, 2013 - 2024 (USD Million)
FIG. 47 Mexico doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 48 MEA doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 49 South Africa doxorubicin market estimates and forecasts, 2013 - 2024 (USD Million)